ANIK
2026 data Public-data reference. official source

Anika Therapeutics, Inc.

Open-data reference.

Measuring Instruments · DE · FY2023
CEO-to-Worker Pay Ratio
41:1
Below Average (Scale: 0–1000:1)
CEO Pay
$4.5M
Median Worker
$109,550
Compensation Pillar

CEO compensation breakdown — pay ratio 41× median worker (Dodd-Frank §953(b) disclosure)

CompensationBase salaryBonusEquityPerksPension
CEO compensation breakdown — pay ratio 41× median worker (Dodd-Frank §953(b) disclosure)

Anika Therapeutics, Inc., a measuring instruments company, reported a CEO-to-worker pay ratio of 41:1 in FY2023. CEO received total compensation of $4.5M, while the median employee earned $109,550 annually. This is below the Measuring Instruments industry median of 108:1 across 98 companies. Data sourced from SEC EDGAR proxy (DEF 14A) filings.

CEO Compensation Breakdown — FY2023

Detailed breakdown not available.

CEO compensation components for Anika Therapeutics, Inc. in fiscal year 2023 as disclosed on SEC EDGAR Form DEF 14A.
Component Amount (USD)
Base Salary
Bonus
Stock Awards
Option Awards
Non-Equity Incentive Plan
Pension Value Change
Other Compensation
Total Compensation$4.5M

Source: SEC EDGAR Form DEF 14A — CIK 898437, FY2023 Summary Compensation Table.

Industry Comparison — Measuring Instruments

This Company's Ratio
41:1
Industry Median Ratio
108:1
Industry Median CEO Pay
$8.4M
This CEO's Pay
$4.5M
Companies in Industry
98
vs. Industry Median
Below
View all companies in Measuring Instruments →

Understanding This Pay Ratio

Anika Therapeutics, Inc.'s CEO-to-worker pay ratio of 41:1 means that earned 41 times more than the company's median employee in FY2023.

The median employee at Anika Therapeutics, Inc. earned $109,550 annually. At that wage, it would take a median employee approximately 41 years to earn what the CEO earned in a single year.

CEO Total Pay

$4.5M

FY2023 Summary Compensation

Pay Ratio

41:1

Below typical industry median

Disclosure Transparency

1.0/5

Limited pay component reporting

Pay-Versus-Performance Disclosure

Under 17 CFR §229.402(v) (the Pay-Versus-Performance rule effective for fiscal years ending after December 16, 2022), issuers must reconcile Compensation Actually Paid (CAP) to Total Shareholder Return (TSR) over a multi-year window. The chart below visualizes the relationship between Anika Therapeutics, Inc.'s reported CAP and TSR for FY2023.

Pay vs Performance — FY2023 (Dodd-Frank §953(a) PvP disclosure)

TSR (%)0CAP realized ($M)4.4598CAP granted ($M)4.4598
Pay vs Performance — FY2023 (Dodd-Frank §953(a) PvP disclosure)

Pay Composition

Equity-based pay (stock + options) 0.0%
Performance-linked (incentive + bonus) 0.0%
Fixed compensation (base salary) 0.0%

ISS QualityScore and Glass-Lewis voting guidelines weight performance-linked share of pay. The CII (Council of Institutional Investors) recommends ≥50% of CEO pay be tied to multi-year performance metrics.

What This 2023 Filing Tells Us About Anika Therapeutics, Inc.

According to the 2023 DEF 14A proxy statement filed with the SEC, Anika Therapeutics, Inc. (ANIK, CIK 898437) reported CEO 's total compensation at $4.5M. That figure is an aggregate of base salary (N/A). The median employee at the firm — the reference point mandated by Section 953(b) of the Dodd-Frank Act — earned $109,550 over the same fiscal year, producing the headline CEO-to-worker pay ratio of 41:1 that this page tracks.

Context matters when reading this ratio. Anika Therapeutics, Inc. operates in the Measuring Instruments sector and is headquartered in DE. Across the Measuring Instruments industry (SIC 38), 98 SEC-reporting companies disclosed pay ratios in FY2023, with a median of 108:1 and an average of 168:1. Median industry CEO pay was $8.4M, so Anika Therapeutics, Inc.'s $4.5M sits at or below that typical figure. That comparison is the fastest way to separate "the CEO is paid like peers" from "this company is an outlier."

Finally, a note on what these SEC numbers do and do not include. Total compensation reported under Item 402 of Regulation S-K reflects grant-date fair value for equity awards, not realized pay, so a CEO may eventually cash in more — or less — depending on stock performance and vesting. The pay ratio itself is calculated against a single median employee chosen under rules that allow statistical sampling, and companies may update methodology year to year. This proxy was filed on 2024-06-11; all figures on this page come directly from that public filing and can be verified against the DEF 14A on the SEC EDGAR system.

Key Data — FY2023

CEO
Total Compensation
$4.5M
Base Salary
N/A
Median Employee Pay
$109,550
Pay Ratio
41:1
Filing Date
2024-06-11

Company Info

Ticker
ANIK
CIK
898437
Industry
Measuring Instruments
SIC Code
3841
State
DE
Data Source: This data is sourced from SEC EDGAR proxy statement (DEF 14A) filings. PlainCEOPay provides this publicly available information for informational purposes only. Not investment or financial advice. Verify with official SEC filings at sec.gov.

Frequently Asked Questions

What is the CEO pay ratio at Anika Therapeutics, Inc.?
Anika Therapeutics, Inc.'s CEO-to-worker pay ratio is 41:1. CEO null earned $4.5M in FY2023, while the median employee earned $109,550.
How much does Anika Therapeutics, Inc.'s CEO earn?
null, CEO of Anika Therapeutics, Inc. (ANIK), earned total compensation of $4.5M in fiscal year 2023, according to SEC proxy filings.
How does Anika Therapeutics, Inc.'s pay ratio compare to its industry?
Anika Therapeutics, Inc.'s pay ratio of 41:1 is below the Measuring Instruments industry median of 108:1. The industry has 98 companies reporting pay ratios.
Where does Anika Therapeutics, Inc.'s CEO pay data come from?
All executive compensation data is sourced from SEC EDGAR DEF 14A proxy statement filings. Companies are required by the Dodd-Frank Act to disclose CEO-to-median-worker pay ratios annually. PlainCEOPay aggregates this publicly available data for easy comparison.
What is included in null's total compensation?
Total compensation of $4.5M includes base salary, stock awards, option awards, non-equity incentive plan compensation, pension value changes, and other compensation as reported in the proxy filing summary compensation table.
How long would it take a median Anika Therapeutics, Inc. employee to earn the CEO's pay?
At a median salary of $109,550, it would take the typical Anika Therapeutics, Inc. employee approximately 41 years to earn what CEO null earned in a single year ($4.5M in FY2023).
All federal data sources used on this page

Related

Data sourced from $official public datasets. See our methodology for details. Retrieved and formatted by PlainCEOPay Editorial